Business
Cantargia Publishes Interim Report for January to September 2025
LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the company's web page www.cantargia.com/en/investors/financial-reports ...
About this update from Cantargia Ab
[{"type":"text","content":"LUND, SE / ACCESS Newswire / November 19, 2025 / Cantargia AB (publ) ("Cantargia") (STO:CANTA) issued its interim report for the period January until September 2025. The report is now available on the company's web page www.cantargia.com/en/investors/financial-reports .","length":284,"tagName":"p"},{"type":"text","content":""This phase of our journey requires clear focus and execution. We have a golden opportunity ahead of us, one that calls for decisive action and operational discipline to match the scientific and regulatory momentum we have built."said Hilde H. Steineger, CEO of Cantargia .","length":284,"tagName":"p"},{"type":"text","content":"Significant events in the third quarter","length":39,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Otsuka Pharmaceuticals acquired CAN10 for an upfront of MUSD 33 plus an additional MUSD 580 in potential milestone payments and up to double digit royalties on future sales.","length":173,"tagName":"p"}]},{"val":[{"type":"text","content":"Preliminary results from the TRIFOUR phase 2 study in TNBC did not demonstrate a difference in overall response rate (ORR) between nadunolimab in combination with chemotherapy vs. chemotherapy alone.","length":199,"tagName":"p"}]},{"val":[{"type":"text","content":"Dr. Hilde H. Steineger was appointed Chief Executive Officer, effective from September 1, 2025.","length":95,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":467,"olType":false},{"type":"text","content":"Significant events after the end of the period","length":46,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Dr. Wolfram Dempke was appointed Chief Medical Officer.","length":55,"tagName":"p"}]}],"tagName":"ul","bulletedList":true,"length":55,"olType":false},{"type":"text","content":"Financial information","length":21,"tagName":"p"},{"type":"text","content":"January - September 2025","length":24,"tagName":"p"},{"type":"list","items":[{"val":[{"type":"text","content":"Net sales: SEK 308.7 M (0.0)","length":28,"tagName":"p"}]},{"val":[{"type":"text","content":"Operating profit: SEK 182.5 M (-127.9)","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Profit after tax: SEK 179.3 M (-122.3)","length":38,"tagName":"p"}]},{"val":[{"type":"text","content":"Earnings per share: SEK 0.72 (-0.67)","length":36...